Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5201277
Max Phase: Preclinical
Molecular Formula: C40H54N10O12S
Molecular Weight: 899.00
Associated Items:
ID: ALA5201277
Max Phase: Preclinical
Molecular Formula: C40H54N10O12S
Molecular Weight: 899.00
Associated Items:
Canonical SMILES: C[C@H]([C@@H]1NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@H](CC(N)=O)NC(=O)[C@@H]2CSc3[nH]c4ccccc4c3C[C@H](NC1=O)C(=O)NCC(=O)N[C@H](C1CCCC1)C(=O)NCC(=O)N2)[C@@H](O)CO
Standard InChI: InChI=1S/C40H54N10O12S/c1-18(28(53)16-51)32-38(61)45-24-11-22-21-8-4-5-9-23(21)47-39(22)63-17-26(35(58)46-25(12-29(41)54)40(62)50-15-20(52)10-27(50)36(59)49-32)44-30(55)13-43-37(60)33(19-6-2-3-7-19)48-31(56)14-42-34(24)57/h4-5,8-9,18-20,24-28,32-33,47,51-53H,2-3,6-7,10-17H2,1H3,(H2,41,54)(H,42,57)(H,43,60)(H,44,55)(H,45,61)(H,46,58)(H,48,56)(H,49,59)/t18-,20+,24-,25-,26-,27-,28-,32-,33+/m0/s1
Standard InChI Key: ISFOBMMQRJURCT-BBNTXBMPSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 899.00 | Molecular Weight (Monoisotopic): 898.3643 | AlogP: -4.50 | #Rotatable Bonds: 6 |
Polar Surface Area: 343.58 | Molecular Species: NEUTRAL | HBA: 13 | HBD: 12 |
#RO5 Violations: 3 | HBA (Lipinski): 22 | HBD (Lipinski): 13 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 10.11 | CX Basic pKa: | CX LogP: -5.89 | CX LogD: -5.89 |
Aromatic Rings: 2 | Heavy Atoms: 63 | QED Weighted: 0.13 | Np Likeness Score: 0.89 |
1. Todorovic M, Rivollier P, Wong AAWL, Wang Z, Pryyma A, Nguyen TT, Newell KC, Froelich J, Perrin DM.. (2022) Rationally Designed Amanitins Achieve Enhanced Cytotoxicity., 65 (15.0): [PMID:35696491] [10.1021/acs.jmedchem.1c02226] |
Source(1):